In acute myeloid leukemia (AML) quiescence and low oxidative state, linked to BCL2 mitochondrial regulation, endow leukemic stem cells (LSC) with treatment-resistance. LSC in CD34 + and more mature CD34 − AML have heterogeneous immunophenotypes overlapping with normal stem/progenitor cells (SPC) but may be differentiated by functional markers. We therefore investigated the oxidative/reactive oxygen species (ROS) profile, its relationship with cell-cycle/BCL2 for normal SPC, and whether altered in AML and myelodysplasia (MDS). In control BM (n = 24), ROS levels were highest in granulocyte-macrophage progenitors (GMP) and CD34 − myeloid precursors but megakaryocyte-erythroid progenitors had equivalent levels to CD34 + CD38 low immature-SPC although they were ki67 high . BCL2 upregulation was specific to GMPs. This profile was also observed for CD34 + SPC in MDS-without-excess-blasts (MDS-noEB, n = 12). Erythroid CD34 − precursors were, however, abnormally ROS-high in MDS-noEB, potentially linking oxidative stress to cell loss. In pre-treatment AML (n = 93) and MDS-with-excess-blasts (MDS-RAEB) (n = 14), immunophenotypic mature-SPC had similar ROS levels to co-existing immature-SPC. However ROS levels varied between AMLs; Flt3ITD 
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Introduction
Recent years have witnessed accelerated interest in the role of reactive oxygen species (ROS) in both normal hematopoietic development and leukemogenesis and in how redox modulation may impact on therapeutic strategies for acute myeloid leukemia (AML) [1, 2] . ROS serve as mediators in proliferation and differentiation of hematopoietic cells, either via a paracrine mechanism [3] , or by intracellular ROS production induced by cytokine receptor engagement on hematopoietic cells [4] [5] [6] [7] . Normal hematopoietic stem cells (HSC) however require fine-tuning of low intracellular ROS levels in order to maintain quiescence, limit oxidative stress damage and sustain lifelong haematopoiesis. The metabolic adjustment of HSCs to reliance on glycolysis with resulting low ROS levels is due to the local conditions of hypoxic bone marrow (BM) niches, and also transcription/signalling pathways that alter ROS homeostasis and are critical for HSC function [8] . Gene targeting of regulatory molecules such as FoxO and Atm leads to higher ROS in HSC and loss of quiescence and self-renewal [9, 10] . Conversely, manipulations that decrease ROS levels cause increased HSC quiescence and loss of effective differentiation into downstream progenitors [11] . Inefficient ROS homeostasis resulting in oxidative stress and genetic instability in HSCs and myeloid progenitors has been linked to myeloid malignancy; [12] [13] [14] for example high ROS levels have been correlated with greater DNA damage in AML with Flt3-internal-tandem-duplication (ITD) [15] and may explain the poor prognosis [16] . Furthermore overproduction of ROS in AML drives growth factor independent proliferation of AML blasts [17, 18] .
Flow cytometric analyses with fluorescent ROS-indicator dyes show that quiescent drugresistant cancer and AML leukemic stem cells (LSC) are enriched in the ROS-low fraction of total tumour cells [2, 19] similarly to normal slow-cycling HSC being enriched in the ROS-low population [20] . Unlike HSC and most cancer cells [21] , AML LSC have increased dependence on oxidative phosphorylation despite maintaining protective low ROS levels [2] . This mitochondrial respiration appears to require BCL2, the overexpression of which has previously been established to have other roles in functional chemo-resistance through anti-apoptosis [22] and potentially by inducing quiescence [23] . These and other mechanisms for BCL2 dependence suggest that chemo-resistant AML LSC may be targeted by the novel BCL2 inhibitor ABT199 /venetoclax [24, 25] . However identifying and tracking chemo-resistant LSCs in patients to evaluate the effectiveness of such new therapies or indeed standard treatments is problematic since xenotransplantation assays are not applicable to routine clinical practice and LSC immunophenotypic profiles are heterogeneous. LSC have been identified within the lineage-negative CD34 + CD38 -/low compartment that contains HSC in normal haematopoiesis [26, 27] but also in 'more mature' CD34 + CD38 + [28] and CD34 − progenitor/precursor compartments [29, 30] . Potentially, low intracellular ROS levels could be used as a differential functional marker of chemo-resistant leukemic stem/progenitor cells (SPC) within immunophenotypic subsets pre-and post-treatment, particularly if combined with quiescence and BCL2 expression. It remains unclear, however, how ROS levels are modulated in the various normal human progenitors downstream from normal HSC compared to their immunophenotypic leukemic counterparts in AML [28] 
Methods

Patient samples
All experiments with human clinical material were performed after receiving approval from the University of Birmingham Research Governance office and the North West-Greater Manchester East Research Ethics Committee (12/NW/0742) and were conducted according to the principles expressed in the Declaration of Helsinki. Human BM and peripheral blood (PB) specimens were residual material from clinical samples for which institutional/ethical approvals were obtained. Control samples were adult (ages 43-84yrs, median 64yrs) lymphoma patient staging BM (n = 24) with no evidence of haematological malignant cells (confirmed by morphology and flow cytometry), and umbilical cord blood (UCB) samples (n = 4). Pre-treatment BM/PB samples from AML patients (n = 93, details in S1 File and S1 Table) and BM samples from myelodysplastic syndrome (MDS)/myeloproliferative disease (MPD) patients were also studied (n = 26, age 32-89yrs, median 76yrs). All samples were between 24-36 hours old. ). For intracellular staining experiments chloro-methyl-DCF was used followed by surface and intracellular staining (ki67/BCL2 and isotype controls). For viability assays, cells were stained with Annexin-V and 7-aminoactinomycin D (7AAD). Data acquisition was performed on a BD-FACS-Canto-II flow cytometer and later analysed with FlowJo (v7.6) software.
Cell staining and flow cytometry
Colony forming unit (CFU) assays
To determine lineage potential FACS-sorted immunophenotypic subsets were seeded into methylcellulose media (Methocult, StemCell Technologies) at 100-1000 cells per dish. CFUdishes were incubated at 37°C, 5%CO 2 for 14-days and then scored for colonies using an inverted light microscope. Specific colony types (CFU-GEMM, CFU-GM, CFU-M, CFU-G and CFU-E) were expressed as percentage of total colony yield under each experimental condition.
Drug sensitivity assays
Freshly isolated (by Ficoll-based density gradient centrifugation) pre-treatment AML patient cells were incubated at 37°C 5%CO 2 with or without ABT199 (Caltag Medsystems) for 16 hours at a range of concentrations in duplicate. Sensitivity to ara-C (Sigma-Aldrich) was measured after incubation with drug for 48 hours. After washing, cells were stained for surface markers and then with Annexin-V and 7AAD. Live/dead cells were then visualized by flow cytometry with toxicity calculated using the formula: %specific apoptosis = (test-control)×100 / (100-control)
Results
ROS levels in control stem/progenitor cells (SPC)
We first asked whether low ROS levels measured with the redox-sensitive probe DCF were restricted to, and could thus differentiate HSC from, other immunophenotypic normal human hematopoietic progenitor populations (S1 Fig) . In control BM samples (n = 24) total CD34 Fig 2A and 2B ). The hierarchy in DCF staining with GMP>CMP>MEP and LMPP>HSC/MPP was also observed in umbilical cord blood (UCB) samples (n = 4) (example in Fig 1B) , suggesting that this ROS profile is representative of normal non-malignant human SPC and not specific to the BM microenvironment.
Lineage fate and viability of CD34 + CD38 high cells with different ROS levels
The relationship between ROS levels and immunophenotypic normal progenitors (CD34 +-
CD38
high fraction) was further assessed by colony assays using purified progenitor subsets from control BM (n = 3 Fig 3B) . CD45RA + cells exclusively generated granulocyte (CFU-G) and macrophage (CFU-M) or mixed GM colonies (CFU-GM) with a relative reduction in CFU-GM and increase in CFU-M observed with increasing DCF (DCF int2 /DCF high fraction) ( Fig 3C) . Thus, higher ROS in the CD45RA − (CMP/MEP-enriched) compartment correlates with reduced multipotency, loss of erythroid potential and commitment towards GMP while higher ROS in the CD45RA + (GMP-enriched) compartment correlates with loss of mixed GM potential and higher macrophage potential. High intracellular ROS levels may predispose GMP to greater risk of apoptosis. In CFU assays, total colony yields were progressively lower with increasing ROS levels (Fig 3D) , suggesting that higher ROS impedes cell proliferation and survival during cell culture. We 
CD117
+ cells were also compared between control BM and CD34 − AML (n = 10) and MDS patient BM samples, using the same colour scheme as above (C). CD34 −
+ cells were subdivided into CD45RA + and CD45RA − cells to enrich for myeloid and erythroid precursors respectively. Median expression and interquartile range is shown on each plot. P values are shown for data-sets where significant differences were observed (p<0.05, Mann Whitney test with 95% confidence intervals).
doi:10.1371/journal.pone.0163291.g002 evaluated cell viability in control BM cells (n = 7) (Fig 3E) . Total CD34 + CD38 low cells and MEP, which are both low for ROS, had the highest viability (>96.5%) while CMP and GMP, which are high in ROS, both had lower frequencies of viable Annexin-V − /7AAD
− cells (86% and 84% respectively). We investigated whether SPCs with higher ROS might be more sensitive to apoptosis by further oxidative insult (such as that generated by chemotherapy) by overnight treatment with the pro-oxidant BSO. This caused increased DCF staining but did not alter the number of apoptotic cells within CMP/GMP subsets (Fig 3F and 3G) , suggesting that these cells have a relative protection against rapid induction of apoptosis from higher ROS levels.
Altered ROS levels in AML and MDS CD34 + cells
We next evaluated the heterogeneity of the leukemic SPC ROS profile in AML patient samples to determine whether more mature immunophenotypic leukemic CMP/GMP subsets might include aberrantly low ROS (putative LSC-enriched [2] ) populations. CD34 + AML (cases with >5% blast cells being CD34 DCF staining was significantly lower in GMP-like (median 3.83) leukemic subsets when compared to the equivalent control SPC (Fig 2A and 2B, p<0 .0001). AML blasts also circulate in peripheral blood (PB) but it is unclear whether ROS profiles of leukemic-SPC are modulated by dissociation from hypoxic BM niches. We compared DCFmeasured ROS levels of CD34 + subsets in unpaired PB (n = 43) and BM (n = 27) presentation (Fig 2C) with no difference observed between unpaired BM (n = 10) and PB (n = 11) samples (S2 Fig) . (Fig 2C) .
ROS levels in AML genetic subgroups
ROS have previously been linked to leukemogenesis of core binding factor (CBF)-AML [31] and genomic instability of Flt3ITD
+ AML [15, 32] . We therefore assessed the relative DCFmeasured ROS levels in these and NPM1 genetic subgroups (cytogenetic/molecularpatient characteristics in S1 Table) In CD34 + AMLs (Fig 4A) , CBF-AMLs (n = 4) had globally higher ROS levels than Flt3ITD In this cohort all Flt3ITD + /NPM1mutated patients (n = 9) were CD34 − AMLs (Fig 4B) . 
Combined analyses of BCL2 / ki67 with ROS in control and AML/MDS SPCs
Although ROS, BCL2 expression and cell-cycle status have previously been functionally linked [2, 23, 33, 34] there are as yet no data assessing these therapeutically relevant parameters in parallel for normal or leukemic SPC subsets. We therefore developed and performed a combined assay on control BM (n = 16), AML diagnosis samples (n = 40) and MDS samples (n = 12). In control BMs CD34 + CD38 high cells expressed higher levels of both ki67 and BCL2 than CD34 + CD38 low cells (example in Fig 5A) . Closer inspection (in 11 cases) showed that although there was no significant difference in ki67 between CMP, GMP and MEP subsets, BCL2 expression followed a GMP>CMP>MEP hierarchy (S3A and (Fig 6A and 6B) .
The observed BCL2 upregulation in the GMP subset suggests that at this myeloid maturation stage when higher ROS levels prime for proliferation/maturation, BCL2 might be transiently expressed for protection against further oxidative stress. In CD34 + AML diagnosis samples (n = 29), a range of ki67 and BCL2 staining was observed − AMLs (n = 11) were also significantly less proliferative and higher for BCL2 than control CD34 − CD117 + cells (Fig 5C) .
Although MDS-noEB (n = 6) had a normal profile, MDS-RAEB CD34 + SPCs (n = 6) were similar to AMLs with a major aberrant ki67 low BCL2 high population in both CD34 + CD38 low and CD34 + CD38 high compartments in all samples, and for some patients (4/6) also in the CD34 − compartment (Fig 6C) . We therefore identified ki67 high phenotype, at least for this more mature CD34 − AML.
We hypothesised that BCL2 over-expression (with downstream effects on apoptosis, metabolic regulation and cell-cycle) might be maintained in ROS-high blasts of some AMLs to counteract further oxidative stress similar to the observed BCL2 upregulation at the GM maturation stage. (Fig 7E) . BCL2 inhibition experiments were performed using ABT199 in a subgroup of pre-treatment AMLs (n = 9). High levels of ABT199 sensitivity (EC50 at or below 100nM) was observed in both CD34
+ and CD34 − AMLs, irrespective of differences in intracellular ROS, BCL2 and cellcycle status. ABT199-induced cell death was greater than that observed using ara-C for 5 of 6 samples (4/4 CD34 + AMLs and 1/2 CD34 − AMLs) where the drug assays were performed in parallel (S7A and S7B Fig) . By combining immunophenotypic characterisation of normal human SPC subsets with a ROS assay we show that although the DCF-low/ROS-low state has been associated with greater quiescence and the DCF-high/ROS-high state with proliferation and differentiation in primitive hematopoietic cells [20] , the more mature (CD34 + CD38 high ) progenitors actually contain a combination of ROS-low and ROS-high cells with MEP consistently ROS-low, and GMP being ROS-high while CMP are a mixture of ROS-high / low cells. Colony assay data support a model whereby ROS-high CMP are pre-committed to become GMP while ROS-low CMP are either less committed and/or pre-committed to MEP. This ROS-based separation of human CMP is consistent with ROS being a driver of myeloid differentiation [6, 7, 35] . Extending our analysis by evaluation of the combined ROS/cell-cycle/BCL2 profile showed that all subsets (GMP/ CMP/MEP) of CD34 + CD38
high cells had high levels of cell-cycle activity despite variation in ROS levels but BCL2 upregulation correlated with increasing ROS levels and was thus myeloid-specific. BCL2 protein upregulation may be a survival cue to counteract oxidative stressinduced apoptosis in GMPs when higher ROS levels are required to prime for proliferation/ maturation. It could also be speculated, however, to predispose GMP to accumulating more DNA damage [36] and explain the relative expansion of GMP rather than CMP as observed in most MDS-RAEB and AML patients [28, 37] . All normal CD34 + CD38 low SPCs were BCL2 low and, as expected, HSC and MPP were ROSlow ki67 low (quiescent) but interestingly the infrequent LMPP population appeared less 'stemcell-like' with higher ROS and greater cell-cycle activity. The immunophenotypically immature SPCs of AML and MDS-RAEB samples had the lowest ROS levels but the overall ROS profile was less heterogeneous compared to normal; the CD34 + CD38 high (GMP-like in particular) and CD34 − AML 'mature' blasts were both lower in ROS than the immunophenotypic equivalent control SPCs. This shift towards immature SPC ROS levels may contribute to the differentiation block in AML, consistent with data showing that agents increasing ROS can induce maturation of AML blasts [38, 39] . The ROS-low pattern was observed, often more distinctly, in AML cells in PB and may represent an adaptation of AML sub-clones in BM that traffic to the PB [40] akin to that of HSPC preserving their hypoxic status while circulating in the normoxic blood environment [41] .
While intracellular ROS levels varied in our cohort (~12-fold range), this was lower than the variation reported for extracellular ROS produced by AML blasts (4-log range) using different methods of ROS detection [18] . It is plausible that extracellular ROS production is also high in our patients while intracellular ROS is kept under control by an enhanced anti-oxidant response [42, 43] , which may be targetable for inhibition [44] [45] . Our data partially support the link between Flt3ITD + mutation and higher ROS levels [15] but also show that ROS levels were lower in most NPM1-mutated/ Flt3ITD + cases (all CD34 − AML in our cohort). Though patient numbers are low, this could suggest that the NPM1-mutated phenotype mitigates the effect of Flt3ITD + on intracellular ROS levels, resulting in a lower risk of DNA damage and progression as suggested by clinical data [46] . Higher ROS levels were also observed in some CBF-AMLs which is interesting as ROS signalling is crucial for maintaining AML1-ETO fusion protein-induced aberrant progenitor cells in a drosophila model [31] . The elevated ROS of CBF-AMLs may be related to both granulocytic maturation and enhanced sensitivity to chemotherapy by the mechanism of ROS-induced apoptosis. We also detected higher ROS than controls in SPCs of MDS-noEB, most marked in the erythroid precursor-enriched subset (CD117
). This may be linked with the reported higher apoptosis and cytopenias observed in MDS patients [37] , did not correlate with early outcome to standard treatment in our small patient group. This is not unexpected as chemo-resistance is also dependent on the balance between activities of different pro-/anti-apoptotic BCL2 family proteins [47] [48] [49] as well as drug efflux activity [50] . Further sub-analysis of ROS highest and ROS lowest cells within the blast population of each patient showed that, although aberrant BCL2 overexpression has been reported as an adaptation of LSC-enriched ROS lowest AML cells [2] , ROS highest cells were also BCL2 high for some CD34 + AMLs (8/24) and CD34 − AMLs (7/9). Intriguingly, aberrant overexpression of BCL2 in ROS highest as well as ROS lowest blasts was the profile most associated with early chemotherapy resistance from limited available data in the 24 CD34 + AMLs with outcome data. However, sensitivity to BCL2 inhibition in vitro using ABT199 in a small number of tested patients was high across both CD34 + and CD34 -AML blast types with different ROS, ki67 and BCL2 levels. Furthermore AML blasts including potentially LSC-enriched fractions, showed greater sensitivity to ABT199 than ara-C. Thus BCL2 dependence was shared by phenotypically different AML blasts. This in vitro data is supportive of greater clinical efficacy of BCL2-inhibition therapy across different AML subtypes compared to standard chemotherapy. It may also be postulated from our results that BCL2 over-expression (with downstream effects on apoptosis, metabolic regulation and cell-cycle) is an adapted 'GM-like' property (to intrinsic or extrinsic dysregulation) that in some AMLs modulates the apoptotic threshold to additional oxidative stress as well as metabolic adjustments. This could contribute to relative chemo-resistance by protecting leukemic blasts with higher ROS from apoptosis triggered by chemotherapy-induced oxidative damage. 
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